BREAST CANCER IN OBESITY: MENOPAUSAL STATUS AND REDOX CHARACTERISTICS OF ADIPOSE TISSUE DYSFUNCTION


I.I. Ganusevich, S.V. Virko, V.O. Riznichuk
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine

DOI: https://doi.org/10.15407/oncology.2023.02.115

 

Summary. Aim: to investigate the levels of superoxide radical (SR) generation and matrix metalloproteinase activity in tumor and adipose tissue adjacent to the tumour (ATA) depending on BMI and menopausal status of breast cancer patients. Object and methods: tumor tissue samples and ATA (postoperative material) from 70 women with breast cancer were studied. The methods used were EPR spectrometry, polyacrylamide gel zymography, general clinical and statistical methods. Results: a significant difference (p < 0.05) in the rate of SR generation at normal weight and obesity was observed in postmenopausal patients, both in the tumour (1.6 times) and in the АТА (1.7 times); there is a significant difference (p < 0.05) in the total activity of MMP-2 and -9 at normal weight and obesity, both in the tumour (2.2 times) and in the АТА (1.9 times). In premenopausal patients with breast cancer with overweight and normal weight do not differ significantly in the frequency of distant metastasis and the overall survival. Рostmenopausal patients with obesity were characterized by a significant (p < 0.05) increase in the frequency of distant metastasis and a decrease in the overall survival. At levels of MMP-2 activity in the ATA above 2.8 units, patients had a significantly shorter life expectancy (p = 0.02) and a higher risk of adverse disease outcome (HR = 2.9) than at lower levels of enzyme activity. Conclusion: the results obtained indicate the prospects for further research and the possibility of using these factors of the tumour microenvironment (SR generation and MMP activity in tumor tissue and ATA) as effective markers of breast cancer prognosis in the presence of overweight.

 

References

  1. Łukasiewicz S, Czeczelewski M, Forma A, et al. Breast cancer-epidemiology, risk factors, classifi ation, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) 2021; 13 (17): 4287. doi: 13390/ cancers13174287.
  2. Smolarz B, Nowak AZ, Romanowicz Breast cancer-epide- miology, classification, pathogenesis and treatment (review of literature). Cancers (Basel) 2022; 14 (10): 2569. https:// doi.org/10.3390/cancers14102569.
  3. Michels KB, Terry KL, Willett Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med 2006; 166 (21): 2395–402. doi: 10.1001/ archinte.166.21.2395.
  4. Berstad P, Coates RJ, Bernstein L, et al. A case-control study of body mass index and breast cancer risk in white and african-american Cancer Epidemiol Biomarkers Prev 2010; 19 (6): 1532–44. doi: 10.1158/1055-9965. EPI-10-0025.
  5. Harris HR, Willett WC, Terry KL, et al. Body fat distribution and risk of premenopausal breast cancer in the nurses’ health study J Natl Cancer Inst 2011; 103 (3): 273–8. doi: 10.1093/jnci/djq500.
  6. Miller Aromatase and the breast: regulation and clinical aspects. Maturitas 2006; 54 (4): 335–41. doi: 10.1016/j. maturitas.2006.04.020.
  7. van Landeghem AA, Poortman J, Nabuurs M, et al. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985; 45 (6): 2900–6. PMID: 398681
  8. Freeman EW, Sammel MD, Lin H, et al. Obesity and reproductive hormone levels in the transition to menopause. Menopause 2010; 17 (4): 718–26. doi: 11097/gme.0b013 e3181cec85d
  9. Lee K, Kruper L, Dieli-Conwright CM, Mortimer The impact of obesity on breast cancer diagnosis and treatment. Current Oncology Reports 2019; 21 (5): 41. doi: 10.1007/ s11912-019-0787-1.
  10. Shaolong Zhang, Pengzhao Shang, Kun Gao, et al. Dynamics of estrogen-induced ROS and DNA strand break generation in estrogen receptor α-positive breast Biochemical and Biophysical Research Communications 2022; 602: 170-8. doi:  10.1016/j.bbrc.2022.02.089.
  11. Colditz G, Peterson Obesity and cancer: evidence, impact, and future directions. Clinical Chemistry 2018; 64 (1):154–62. doi: 10.1373/clinchem.2017.277376.
  12. Alexandre L, Long E, Beales Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol 2014; 5 (4): 534-49. doi: 10.4291%2Fwjgp.v5.i4.534.
  13. Reaves DK, Ginsburg E, Bang JJ, et al. Persistent organic pollutants & obesity: potential mechanisms for breast cancer Endocr relat cancer 2015; 22 (2): 69–86. doi: 10.1530/erc-14-0411.
  14. Abdel-Hamid, NM, Abass, et Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting. Mol Biol Rep 2021; 48: 6525–38. doi: 10.1007/s11033-021-06635-z.
  15. WHO Mean Body Mass Index (BMI). World Health Organization 2019, 5. https://www.whint/europe/news-room/ fact-sheets/item/a-healthy-lifestyle—who-recommendations.
  16. De Clerk YA, Perez N, Shimada et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer research 1992; 52: 701-8. PMID: https://pubmed.ncbi.nlm.nih.gov/1732058/.
  17. Burlaka AP, Sidorik EP, Ganusevich II, et al. High formation of superoxide anion and nitric oxide, and matrix metallo- proteinases activity in vascular wall of rectal carcinoma ves- Exp Oncol 2006; 28: 323–5. PMID: https://pubmed. ncbi.nlm.nih.gov/17285119/.
  18. Kawai T, Autieri MV, Scalia Adipose tissue infltion and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 2021; 320 (3): C375-C391. doi: 10.1152/ajpcell. 00379.2020.
  19. Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through Am J Prev Med 2012; 42 (6): 563–70. doi: 10.1016/j.amepre.2011.10.026.
  20. Guthold R, Stevens GA, Riley LM, et al. Worldwide trends in insufficient physical activity from 2001 to 2016: A pooled analysis of 358 population-based surveys with 9 million participants. Lancet Glob Health 2018; 6 (10): e1077–86. doi: 10.1016/S2214-109X(18)30357-7.
  21. Collaboration Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 pros- pective studies. Lancet 2009; 373 (9669): 1083–96. doi: 10.1016/S0140-6736(09)60318-4.
  22. Bray GA, Kim KK, Wilding JPH, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity F Obes Rev 2017; 18 (7): 715–23. doi: 10.1111/obr.12551.
  23. Phung, Tin Tin, S & Elwood, et al. Prognostic models for breast cancer: a systematic review. BMC Cancer 2019; 19: doi: 10.1186/s12885-019-5442-6.
  24. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer Am J Epidemiol 2000; 152 (6): 514–27. doi: 10.1093/aje/152.6.514.
  25. Bergstrom A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Int J Cancer 2001;91 (3): 421–30. doi: 10.1002/1097-0215(200002)9999:9999<:: AID-IJ 053>3.0.CO;2-T.
  26. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta- analysis of prospective observational studies. Lancet 2008; 371 (9612): 569–7 doi: 10.1016/S0140-6736(08) 60269-X.
  27. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the million women study: cohort BMJ 2007; 335 (7630): 1134. doi: 10.1136/bmj.39367.495995.AE.
  28. Rosenberg LU, Einarsdottir K, Friman EI, et al. Risk factors for hormone receptor-defi ed breast cancer in post- menopausal Cancer Epidemiol Biomarkers Prev 2006; 15 (12): 2482–8. doi: 10.1158/1055-9965.EPI-06- 0489.
  29. Neuhouser ML, Aragaki AK, Prentice RL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical JAMA Oncol 2015; 1 (5): 611–21. doi: 10.1001/jamaoncol.2015.1546.

No comments » Add comment